Yizhou Li

Yizhou Li

Auto-generated profile, based on publicly available information

Yizhou Li

Chongqing Key Laboratory of Natural Product Synthesis and Drug Research, Innovative Drug Research Center, School of Pharmaceutical Sciences, Chongqing University, Chongqing, China

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 February 2008 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
SYShang‐Dong Yang
Shang‐Dong Yang
CSChang‐Liang Sun
Chang‐Liang Sun
ZFZhao Fang
Zhao Fang
BLBi‐Jie Li
Bi‐Jie Li
YLYi‐Zhou Li
Yi‐Zhou Li
ZSZhang‐Jie Shi
Zhang‐Jie Shi

27 May 2007 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
GCGuixin Cai
Guixin Cai
YFYe Fu
Ye Fu
YLYizhou Li
Yizhou Li
XWXiaobing Wan
Xiaobing Wan
ZSZhangjie Shi
Zhangjie Shi

4 May 2009 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
YLYi‐Zhou Li
Yi‐Zhou Li
BLBi‐Jie Li
Bi‐Jie Li
XLXing‐Yu Lu
Xing‐Yu Lu
SLSong Lin
Song Lin
ZSZhang‐Jie Shi
Zhang‐Jie Shi

12 December 2008 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
BLBi‐Jie Li
Bi‐Jie Li
YLYi‐Zhou Li
Yi‐Zhou Li
XLXing‐Yu Lu
Xing‐Yu Lu
JLJia Liu
Jia Liu
BGBing‐Tao Guan
Bing‐Tao Guan
ZSZhang‐Jie Shi
Zhang‐Jie Shi

10 November 2014 in Nature Chemical Biology
Verified
Journal Article
Open access
PDF file
XCXinping Chen
Xinping Chen
CZChunyue Zhao
Chunyue Zhao
XLXiaolong Li
Xiaolong Li
TWTao Wang
Tao Wang
YLYizhou Li
Yizhou Li
LLLei Liu
Lei Liu
The α1-adrenergic receptor antagonist terazosin protects flies and mammalian cells from stress and apoptosis through direct activation of the glycolytic enzyme phosphoglycerate kinase 1, which interacts with Hsp90 to promote ATP consumption. Drugs that can protect against organ damage are urgently needed, especially for diseases such as sepsis and brain stroke. We discovered that terazosin (TZ), a widely marketed α1-adrenergic receptor antagonist, alleviated organ damage and improved survival in rodent models of stroke and sepsis. Through combined studies of enzymology and X-ray crystallography, we discovered that TZ binds a new target, phosphoglycerate kinase 1 (Pgk1), and activates its enzymatic activity, probably through 2,4-diamino-6,7-dimethoxyisoquinoline′s ability to promote ATP release from Pgk1. Mechanistically, the ATP generated from Pgk1 may enhance the chaperone activity of Hsp90, an ATPase known to associate with Pgk1. Upon activation, Hsp90 promotes multistress resistance. Our studies demonstrate that TZ has a new protein target, Pgk1, and reveal its corresponding biological effect. As a clinical drug, TZ may be quickly translated into treatments for diseases including stroke and sepsis.

29 May 2018 in eLife
Verified
Journal Article
Open access
NSNatasa Savic
Natasa Savic
FRFemke Cecilia Akke Sipkje Ringnalda
Femke Cecilia Akke Sipkje Ringnalda
HLHelen Lindsay
Helen Lindsay
CBChristian Berk
Christian Berk
KBKatja Bargsten
Katja Bargsten
GSGerald Schwank
Gerald Schwank
The CRISPR-Cas9 targeted nuclease technology allows the insertion of genetic modifications with single base-pair precision. The preference of mammalian cells to repair Cas9-induced DNA double-strand breaks via error-prone end-joining pathways rather than via homology-directed repair mechanisms, however, leads to relatively low rates of precise editing from donor DNA. Here we show that spatial and temporal co-localization of the donor template and Cas9 via covalent linkage increases the correction rates up to 24-fold, and demonstrate that the effect is mainly caused by an increase of donor template concentration in the nucleus. Enhanced correction rates were observed in multiple cell types and on different genomic loci, suggesting that covalently linking the donor template to the Cas9 complex provides advantages for clinical applications where high-fidelity repair is desired.